Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results
November 14, 2018 06:30 ET
|
Novan, Inc.
Higher rates of complete clearance of all molluscum lesions at Week 12 for the two highest doses, SB206 8% and 12% twice-daily, more than double the rate observed in the vehicle groupClear treatment...
Novan Announces Corporate Update Conference Call and Webcast
November 12, 2018 08:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Wednesday, November 14, at...
Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases
November 01, 2018 08:05 ET
|
Novan, Inc.
Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in DermatologySB206 was efficacious and well tolerated in the trialAdvancement of the late...
Novan Creates Dedicated Women’s Health Business Unit
October 25, 2018 07:05 ET
|
Novan, Inc.
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical...
Novan Extends Technical Production Capacity and Reaches Agreement with Orion Corporation
October 16, 2018 08:05 ET
|
Novan, Inc.
External manufacturing agreement reached to enable production of clinical trial materials for SB204 and the acne indication, with the potential to include additional product candidatesExtension of...
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
October 08, 2018 08:00 ET
|
Novan, Inc.
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November
October 01, 2018 08:05 ET
|
Novan, Inc.
Trial enrollment completed meaningfully ahead of scheduleTop line results targeted to be communicated no later than mid-NovemberFavorable and consistent safety profile of SB206 enabled escalation to...
Novan Receives FDA Guidance for SB204 and Acne Indication
September 24, 2018 16:15 ET
|
Novan, Inc.
Written minutes received from Type C meeting with FDAModerate-to-severe patient pathway re-affirmedAdditional insights gained around the severe patient sub-population MORRISVILLE, N.C., Sept. 24,...
Novan Announces Promising Clinical Results with SB414
August 20, 2018 06:30 ET
|
Novan, Inc.
In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide...
Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract
August 08, 2018 08:25 ET
|
Novan, Inc.
Company provides a comprehensive business update via its second quarter 2018 Form 10-Q filingNew incentive plan is aligned with the achievement of two specific stockholder value targets and is...